Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) CEO Stanley T. Crooke sold 11,000 shares of the company’s stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $33.46, for a total value of $368,060.00. Following the completion of the sale, the chief executive officer now directly owns 6,941 shares in the company, valued at approximately $232,246. The transaction was disclosed in a document filed with the SEC, which is available at this link.

ISIS has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, June 5th. They now have a $29.00 price target on the stock. Separately, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Finally, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $41.10.

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) traded down 2.01% on Thursday, hitting $32.24. 1,880,659 shares of the company’s stock traded hands. ISIS Pharmaceuticals has a 52-week low of $20.52 and a 52-week high of $62.66. The stock’s 50-day moving average is $27.99 and its 200-day moving average is $40.07. The company’s market cap is $3.791 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last announced its earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.04. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $35.12 million. During the same quarter last year, the company posted ($0.02) earnings per share. ISIS Pharmaceuticals’s revenue was down 35.0% compared to the same quarter last year. On average, analysts predict that ISIS Pharmaceuticals will post $-0.71 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.